These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7804369)

  • 1. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis.
    Jones M; Philip T; Palmer P; von der Maase H; Vinke J; Elson P; Franks CR; Selby P
    Cancer Biother; 1993; 8(4):275-88. PubMed ID: 7804369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J; Kirchner H; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of 2 modes of administration of recombinant interleukin-2: continuous intravenous infusion alone versus subcutaneous administration plus interferon alpha in patients with advanced renal cell carcinoma.
    Palmer PA; Atzpodien J; Philip T; Negrier S; Kirchner H; Von der Maase H; Geertsen P; Evers P; Loriaux E; Oskam R
    Cancer Biother; 1993; 8(2):123-36. PubMed ID: 7804353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
    Lopez Hänninen E; Kirchner H; Atzpodien J
    J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.
    Besana C; Borri A; Bucci E; Citterio G; Di Lucca G; Fortis C; Matteucci P; Tognella S; Tresoldi M; Baiocchi C
    Eur J Cancer; 1994; 30A(9):1292-8. PubMed ID: 7999416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
    Fyfe G; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC
    J Clin Oncol; 1995 Mar; 13(3):688-96. PubMed ID: 7884429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of continuous intravenous infusion of recombinant interleukin-2 in patients with advanced renal cell carcinoma.
    Lopez M; Carpano S; Cancrini A; Marcellini M; Del Medico P; Rinaldi M; Vici P; Paoletti G; Di Lauro L
    Ann Oncol; 1993 Sep; 4(8):689-91. PubMed ID: 8241001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical application of continuous infusion of recombinant interleukin-2.
    West WH
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S11-5. PubMed ID: 2627985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study.
    Geertsen PF; Hermann GG; von der Maase H; Steven K
    J Clin Oncol; 1992 May; 10(5):753-9. PubMed ID: 1569448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma.
    Palmer PA; Vinke J; Evers P; Pourreau C; Oskam R; Roest G; Vlems F; Becker L; Loriaux E; Franks CR
    Eur J Cancer; 1992; 28A(6-7):1038-44. PubMed ID: 1627369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study.
    Bukowski RM; Goodman P; Crawford ED; Sergi JS; Redman BG; Whitehead RP
    J Natl Cancer Inst; 1990 Jan; 82(2):143-6. PubMed ID: 2294224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic renal cell carcinoma: long-term survival after therapy with high-dose continuous-infusion interleukin-2.
    Gold PJ; Thompson JA; Markowitz DR; Neumann S; Fefer A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S85-91. PubMed ID: 9457401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
    Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival in patients with metastatic renal cell carcinoma treated with continuous intravenous infusion of recombinant interleukin-2: the experience of a single institution.
    Libra M; Talamini R; Crivellari D; Buonadonna A; Freschi A; Stefanovski P; Berretta M; De Cicco M; Balestreri L; Merlo A; Volpe R; Galligioni E; Sorio R
    Tumori; 2003; 89(4):400-4. PubMed ID: 14606643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A; Savona S; Gafney E; Penichet KO; Lin BY; Levitt D; Ahmed T; Arlin ZA; Baskind P; Needleman D
    J Biol Response Mod; 1989 Oct; 8(5):468-78. PubMed ID: 2795092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
    Yang JC; Rosenberg SA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S79-84. PubMed ID: 9457400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.